Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR

PHASE4CompletedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

August 31, 2014

Conditions
Allergic Rhinitis
Interventions
DRUG

205.5 mcg of azelastine hydrochloride

nasal spray

DRUG

137 mcg of azelastine hydrochloride

nasal spray

Trial Locations (14)

29406

National Allergy, Asthna & Urticaria Centers of Charleston Pa, Charleston

35209

Clinical Research Center of Alabama,LLC, Birmingham

61761

Sneeze, Wheeze and Itch Associates, Normal

72205

Little Rock Allergy and Asthma Clinical research Center, Little Rock

73120

Allergy, Asthma & Clinical Research Center, Oklahoma City

75246

Texas Allergy Research Center, Dallas

76712

Allergy and Asthma Center, Waco

Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco, Waco

78130

Central Texas Health Research, New Braunfels

78229

Paul H Ratner,MD, San Antonio

78233

Live Oak Allergy and Asthma Clinic, San Antonio

80907

Storms Clinical Research Institute, Colorado Springs

92626

West Coast Clinical Trials, Costa Mesa

92691

Southern California Research, Mission Viejo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novella Clinical

OTHER

lead

Meda Pharmaceuticals

INDUSTRY